N
News Analysis
pharmiweb.com

www.pharmiweb.com ·

Negative

Medpace Holdings Inc Reports First Quarter 2026 Results

Private Sector DevelopmentInnovation Technology And Ent…Intellectual PropertyFirm Innovation Productivity …

All NewsRead the full story on pharmiweb.com

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.

AI insight

AI-generated

Medpace is a CRO (Contract Research Organization) serving biopharma. Revenue growth and book-to-bill indicate strong demand for clinical trial services. The resignation of the president introduces management transition risk but no immediate commercial disruption. No direct commodity or supply chain impact.

Signals our AI researcher identified

Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.

  • Revenue $706.6M, +26.5% YoY
  • Net new business awards $618.4M, +23.7% YoY
  • Net book-to-bill ratio 0.88x
  • GAAP net income $123.9M, +8.1% YoY
  • President Jesse Geiger resigns effective May 31, 2026

About the publisher

pharmiweb.com is one of the en-language news outlets that News Analysis aggregates. Coverage from this source appears in our global feed alongside the publisher's own reporting.

Topic context

pharmiweb.com files this story under "private sector development" in the GDELT knowledge graph. News Analysis surfaces coverage based on the same open classification taxonomy.

Medpace Holdings Inc Reports First Quarter 2026 Results — News Analysis